All In Biotech

NDA 017538 · Curium

Technescan Pyp Kit

Technetium Tc-99m Pyrophosphate Kit · Injection

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

May 28, 1974

Approved uses

2

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

33

25 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

INDICATIONS AND USAGE Technescan PYP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for: • Skeletal imaging to demonstrate areas of altered osteogenesis in adults • Cardiac imaging as an adjunct in the diagnosis of acute myocardial infarction in adults (See WARNINGS ) Technescan PYP, in conjunction with sodium pertechnetate Tc 99m injection for red blood cell (RBC) labeling, is indicated for gated cardiac blood pool imaging and for the detection of gastrointestinal bleeding sites in adults.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 30, 1989 Supplement 11 · Efficacy
  • May 28, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • TECHNESCAN PYP KIT · TECHNETIUM TC-99M PYROPHOSPHATE KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Pyrophosphate Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness6
  • hyperhidrosis6
  • syncope5
  • vomiting5
  • drug ineffective3
  • dyspnoea3
  • hypotension3
  • loss of consciousness3
  • blood pressure decreased2
  • body temperature increased2
  • cardiac arrest2
  • cold sweat2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
20171
20183
20193
202019
20211
20222
20241
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 17, 2026

    Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20). Shortage of an active ingredient

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Curium

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.